Brief: Verona Pharma Says Nuance Pharma Receives Clearance To Begin Pivotal Clinical Trials With Ensifentrine For COPD In China
19/08/2022 12:30
Aug 19 (Reuters) - Verona Pharma PLC I9SAy.F :
* NUANCE PHARMA RECEIVES CLEARANCE TO BEGIN PIVOTAL CLINICAL
TRIALS WITH ENSIFENTRINE FOR COPD IN CHINA
Source text for Eikon: ID:nGNX4h3wjf
Further company coverage: I9SAy.F
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Verona Pharma
See all newsBrief: Acquisition Of Verona By Msd Approved By The High Court Of Justice Of England And Wales
Brief: Shareholders Of Verona Pharma Approve Proposed Acquisition By Merck
US corporate debt market returns in force after market holiday
Merck to cut jobs and costs as demand for Gardasil in China remains weak (updated)
Merck to cut jobs and costs as demand for Gardasil in China remains weak